Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Bosentan treatment for Raynauds phenomenon and skin fibrosis in patients with Systemic Sclerosis and pulmonary arterial hypertension: an open-label, observational, retrospective study.

Giordano N, Puccetti L, Papakostas P, Di Pietra N, Bruni F, Pasqui AL, Acampa M, Bocchi V, Donati V, Voglino M, Fioravanti A, Montella A, Auteri A, Nuti R, Pastorelli M.

Int J Immunopathol Pharmacol. 2010 Oct-Dec;23(4):1185-94.

PMID:
21244767
2.

Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial.

Kuhn A, Haust M, Ruland V, Weber R, Verde P, Felder G, Ohmann C, Gensch K, Ruzicka T.

Rheumatology (Oxford). 2010 Jul;49(7):1336-45. doi: 10.1093/rheumatology/keq077.

3.

Low occurrence of digital ulcers in scleroderma patients treated with bosentan for pulmonary arterial hypertension: a retrospective case-control study.

Cozzi F, Pigatto E, Rizzo M, Favaro M, Zanatta E, Cardarelli S, Riato L, Punzi L.

Clin Rheumatol. 2013 May;32(5):679-83. doi: 10.1007/s10067-013-2172-z.

PMID:
23344686
4.

Effects of bosentan on the skin lesions: an observational study from a single center in Japan.

Funauchi M, Kishimoto K, Shimazu H, Nagare Y, Hino S, Yano T, Kinoshita K.

Rheumatol Int. 2009 May;29(7):769-75. doi: 10.1007/s00296-008-0789-z.

PMID:
19037604
5.

Bosentan improves skin perfusion of hands in patients with systemic sclerosis with pulmonary arterial hypertension.

Rosato E, Molinaro I, Borghese F, Rossi C, Pisarri S, Salsano F.

J Rheumatol. 2010 Dec;37(12):2531-9. doi: 10.3899/jrheum.100358.

PMID:
20810512
6.
7.

Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study.

Nguyen VA, Eisendle K, Gruber I, Hugl B, Reider D, Reider N.

Rheumatology (Oxford). 2010 Mar;49(3):583-7. doi: 10.1093/rheumatology/kep413.

8.

Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.

Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, Rich E, Carpentier P, Molitor J, Seibold JR, Hsu V, Guillevin L, Chatterjee S, Peter HH, Coppock J, Herrick A, Merkel PA, Simms R, Denton CP, Furst D, Nguyen N, Gaitonde M, Black C.

Arthritis Rheum. 2004 Dec;50(12):3985-93.

9.

Bosentan in systemic sclerosis.

Heresi GA, Minai OA.

Drugs Today (Barc). 2008 Jun;44(6):415-28. doi: 10.1358/dot.2008.44.6.1220138. Review.

PMID:
18596996
10.

[Bosentan for treatment of active digital ulcers in patients with systemic sclerosis].

Launay D, Diot E, Pasquier E, Mouthon L, Boullanger N, Fain O, Jego P, Carpentier P, Hatron PY, Hachulla E.

Presse Med. 2006 Apr;35(4 Pt 1):587-92. French.

11.

Endothelin receptor antagonist bosentan improves the dermal sclerosis in a patient with systemic sclerosis.

Nishibu A, Sakai E, Oyama N, Yamamoto T.

Australas J Dermatol. 2012 May;53(2):e32-3. doi: 10.1111/j.1440-0960.2010.00719.x.

PMID:
22571581
12.

Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease.

Ahmadi-Simab K, Hellmich B, Gross WL.

Eur J Clin Invest. 2006 Sep;36 Suppl 3:44-8.

PMID:
16919010
13.

Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan.

Selenko-Gebauer N, Duschek N, Minimair G, Stingl G, Karlhofer F.

Rheumatology (Oxford). 2006 Oct;45 Suppl 3:iii45-8. Erratum in: Rheumatology (Oxford). 2008 Feb;47(2):234-5.

14.

Bosentan therapy for pulmonary arterial hypertension.

Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G.

N Engl J Med. 2002 Mar 21;346(12):896-903. Erratum in: N Engl J Med 2002 Apr 18;346(16):1258.

15.

Survival in patients with pulmonary arterial hypertension treated with first-line bosentan.

McLaughlin VV.

Eur J Clin Invest. 2006 Sep;36 Suppl 3:10-5.

PMID:
16919005
17.

Evaluation of the effect of Bosentan treatment on proinflammatory cytokine serum levels in patients affected by Systemic Sclerosis.

Bellisai F, Morozzi G, Scaccia F, Chellini F, Simpatico A, Pecetti G, Galeazzi M.

Int J Immunopathol Pharmacol. 2011 Jan-Mar;24(1):261-4.

PMID:
21496413
18.
19.

Bosentan: a review of its use in pulmonary arterial hypertension and systemic sclerosis.

Oldfield V, Lyseng-Williamson KA.

Am J Cardiovasc Drugs. 2006;6(3):189-208. Review.

PMID:
16780392
20.

Longterm effects of endothelin receptor antagonism on microvascular damage evaluated by nailfold capillaroscopic analysis in systemic sclerosis.

Cutolo M, Zampogna G, Vremis L, Smith V, Pizzorni C, Sulli A.

J Rheumatol. 2013 Jan;40(1):40-5. doi: 10.3899/jrheum.120416.

PMID:
23118114
Items per page

Supplemental Content

Support Center